Cargando…

Antisense Technology: An Emerging Platform for Cardiovascular Disease Therapeutics

Antisense oligonucleotides and small interfering RNAs, which suppress the translation of specific mRNA target proteins, are emerging as important therapeutic modalities for the treatment of cardiovascular disease. Over the last 25 years, the advances in all aspects of antisense technology, as well a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Richard G., Crosby, Jeff, Baker, Brenda F., Graham, Mark J., Crooke, Rosanne M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3838598/ https://www.ncbi.nlm.nih.gov/pubmed/23856914 http://dx.doi.org/10.1007/s12265-013-9495-7

Ejemplares similares

Antisense technology: A review
por: Crooke, Stanley T., et al.
Publicado: (2021)

Effects of an Antisense Oligonucleotide Inhibitor of C‐Reactive Protein Synthesis on the Endotoxin Challenge Response in Healthy Human Male Volunteers
por: Noveck, Robert, et al.
Publicado: (2014)

Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (Kynamro(®)): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B
por: Geary, Richard S., et al.
Publicado: (2015)

Antisense oligonucleotide inhibition of cholesteryl ester transfer protein enhances RCT in hyperlipidemic, CETP transgenic, LDLr(−/−) mice
por: Bell, Thomas A., et al.
Publicado: (2013)

Antisense oligonucleotides targeting angiotensinogen: insights from animal studies
por: Wu, Chia-Hua, et al.
Publicado: (2019)

CD40 Generation 2.5 Antisense Oligonucleotide Treatment Attenuates Doxorubicin-induced Nephropathy and Kidney Inflammation
por: Donner, Aaron J, et al.
Publicado: (2015)

Antisense oligonucleotides targeting translation inhibitory elements in 5′ UTRs can selectively increase protein levels
por: Liang, Xue-hai, et al.
Publicado: (2017)

Molecular Mechanisms of Antisense Oligonucleotides
por: Crooke, Stanley T.
Publicado: (2017)

Antisense oligonucleotide–mediated inhibition of angiopoietin-like protein 3 increases reverse cholesterol transport in mice
por: Bell, Thomas A., et al.
Publicado: (2021)

Effects of Antisense Oligonucleotides against C-Reactive Protein on the Development of Atherosclerosis in WHHL Rabbits
por: Yu, Qi, et al.
Publicado: (2014)

Integrated Assessment of the Clinical Performance of GalNAc(3)-Conjugated 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience
por: Crooke, Stanley T., et al.
Publicado: (2019)

The Effects of 2′-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials
por: Crooke, Stanley T., et al.
Publicado: (2017)

Evaluation of an Anti-Tumor Necrosis Factor Therapeutic in a Mouse Model of Niemann-Pick C Liver Disease
por: Vincent, Melanie, et al.
Publicado: (2010)

Defining the Factors That Contribute to On-Target Specificity of Antisense Oligonucleotides
por: Lima, Walt F., et al.
Publicado: (2014)

Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides
por: Anderson, Brooke A, et al.
Publicado: (2021)

Antisense antimicrobial therapeutics
por: Sully, Erin K, et al.
Publicado: (2016)

Annexin A2 facilitates endocytic trafficking of antisense oligonucleotides
por: Wang, Shiyu, et al.
Publicado: (2016)

Integrated Safety Assessment of 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers
por: Crooke, Stanley T, et al.
Publicado: (2016)

From Antisense RNA to RNA Modification: Therapeutic Potential of RNA-Based Technologies
por: Adachi, Hironori, et al.
Publicado: (2021)

Membrane Destabilization Induced by Lipid Species Increases Activity of Phosphorothioate-Antisense Oligonucleotides
por: Wang, Shiyu, et al.
Publicado: (2018)

Nucleic acid binding proteins affect the subcellular distribution of phosphorothioate antisense oligonucleotides
por: Bailey, Jeffrey K., et al.
Publicado: (2017)

The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA
por: Vickers, Timothy A., et al.
Publicado: (2015)

Mouse genome-wide association studies and systems genetics uncover the genetic architecture associated with hepatic pharmacokinetic and pharmacodynamic properties of a constrained ethyl antisense oligonucleotide targeting Malat1
por: Pirie, Elaine, et al.
Publicado: (2018)

Antisense Oligonucleotide Technologies to Combat Obesity and Fatty Liver Disease
por: Keating, Michael F., et al.
Publicado: (2022)

RNA cleavage products generated by antisense oligonucleotides and siRNAs are processed by the RNA surveillance machinery
por: Lima, Walt F., et al.
Publicado: (2016)

Facile accelerated specific therapeutic (FAST) platform develops antisense therapies to counter multidrug-resistant bacteria
por: Eller, Kristen A., et al.
Publicado: (2021)

Emerging liver organoid platforms and technologies
por: Lam, Do Thuy Uyen Ha, et al.
Publicado: (2021)

Antisense Oligonucleotides Capable of Promoting Specific Target mRNA Reduction via Competing RNase H1-Dependent and Independent Mechanisms
por: Vickers, Timothy A., et al.
Publicado: (2014)

A Selective Inhibitor of Human C-reactive Protein Translation Is Efficacious In Vitro and in C-reactive Protein Transgenic Mice and Humans
por: Jones, Nicholas R, et al.
Publicado: (2012)

Antisense therapeutics in oncology: current status
por: Farooqi, Ammad Ahmad, et al.
Publicado: (2014)

Inhibiting C-Reactive Protein for the Treatment of Cardiovascular Disease: Promising Evidence from Rodent Models
por: Szalai, Alexander J., et al.
Publicado: (2014)

Translation can affect the antisense activity of RNase H1-dependent oligonucleotides targeting mRNAs
por: Liang, Xue-Hai, et al.
Publicado: (2018)

Advances of Antisense Oligonucleotide Technology in the Treatment of Hereditary Neurodegenerative Diseases
por: Lin, Mengsi, et al.
Publicado: (2021)

mRNA levels can be reduced by antisense oligonucleotides via no-go decay pathway
por: Liang, Xue-hai, et al.
Publicado: (2019)

Intra-endosomal trafficking mediated by lysobisphosphatidic acid contributes to intracellular release of phosphorothioate-modified antisense oligonucleotides
por: Wang, Shiyu, et al.
Publicado: (2017)

RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus
por: Liang, Xue-Hai, et al.
Publicado: (2017)

Enhancement of SMN2 Exon 7 Inclusion by Antisense Oligonucleotides Targeting the Exon
por: Hua, Yimin, et al.
Publicado: (2007)

Targeting of Repeated Sequences Unique to a Gene Results in Significant Increases in Antisense Oligonucleotide Potency
por: Vickers, Timothy A., et al.
Publicado: (2014)

Improvements in the Tolerability Profile of 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides in Parallel with Advances in Design, Screening, and Other Methods
por: Partridge, Wesley, et al.
Publicado: (2021)

PFRED: A computational platform for siRNA and antisense oligonucleotides design
por: Sciabola, Simone, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p262adcvfm3mlifp1h6h29kufm